*  Annexin 1-derived peptide Ac2-26 inhibits eosinophil recruitment in vivo via decreasing prostaglandin Dâ‚‚.
Dose-Response Relationship, Immunologic. Eosinophils / drug effects, immunology*. Female. Immunoglobulin E / blood, immunology ... Previous Document: Ability of pollen cytoplasmic granules to induce biased allergic responses in a rat model.. Next Document: ...
  http://www.biomedsearch.com/nih/Annexin-1-Derived-Peptide-Ac2/20733322.html
*  "Gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory " by Robert K. Furse, Ronald G. Rossetti et al.
... is attributable to autoinduction and that GLA reduces autoinduction of IL-1beta while leaving the initial IL-1beta response to ... Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Female; Gene Expression Regulation; Humans; ... is attributable to autoinduction and that GLA reduces autoinduction of IL-1beta while leaving the initial IL-1beta response to ...
  https://escholarship.umassmed.edu/oapubs/1126/
*  Effect of anti-GM-CSF treatment prior to the onset of a | Open-i
Dose-Response Relationship, Immunologic. *Enzyme-Linked Immunosorbent Assay. *Hindlimb/drug effects/pathology ... Control mice received the highest dose (300 ?g) of control mAb. There was a dose-related suppression of the clinical score, ... Control mice received the highest dose (300 ?g) of control mAb. There was a dose-related suppression of the clinical score, ... Mentions: Mice were treated i.p. with increasing doses of anti-GM-CSF (30, 100, and 300 ?g) beginning at day 21, and then every ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC64841_AR-3-5-293-5&req=4
*  The effect of dosing schedule on tumor response rate. G | Open-i
The effect of dosing schedule on tumor response rate. Groups of nine mice were treated with HB22.7 before Raji NHL tumors had ... Dose-Response Relationship, Immunologic. *Drug Administration Schedule. *Humans. *Mice. *Mice, Inbred BALB C ... Fig3: The effect of dosing schedule on tumor response rate. Groups of nine mice were treated with HB22.7 before Raji NHL tumors ... Fig3: The effect of dosing schedule on tumor response rate. Groups of nine mice were treated with HB22.7 before Raji NHL tumors ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC2749165_262_2009_713_Fig3_HTML&req=4
*  Dose-related reduction in allergen-specific T cells associates with clinical response of atopic dermatitis to methotrexate. -...
Dose-Response Relationship, Drug, Dose-Response Relationship, Immunologic, Female, HLA-A Antigens, HLA-DRB1 Chains, Humans, ... Dose-related reduction in allergen-specific T cells associates with clinical response of atopic dermatitis to methotrexate. ... Dose-related reduction in allergen-specific T cells associates with clinical response of atopic dermatitis to methotrexate. ...
  https://www.imm.ox.ac.uk/publications/3467
*  Interleukin-4 promotes human CD8 T cell expression of CCR7. - Radcliffe Department of Medicine
Dose-Response Relationship, Immunologic, Humans, Interleukin-4, Interleukins, Lymphocyte Activation, Receptors, CCR7, Receptors ...
  https://www.rdm.ox.ac.uk/publications/17503
*  Foetal exposure to maternal depression predicts cortisol responses in infants: findings from rural South India. - Nuffield...
In addition, the dose-response relationship between foetal exposure to antenatal depression and infant cortisol reactivity is ... to explore whether the relationship is dose-dependent. RESULTS: Exposure to antenatal depression independently predicted ... Salivary cortisol response to immunization was measured in 58 infants at 2 months of age. We aimed (i) to investigate the ... CONCLUSIONS: These findings suggest that the association between antenatal depression and infant cortisol reactivity is dose- ...
  https://www.obs-gyn.ox.ac.uk/publications/522127
*  Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Interferon-beta / immunology, therapeutic use*. ... Adjuvants, Immunologic / therapeutic use*. Adult. Antibodies / blood. Cross-Sectional Studies. Disability Evaluation. ... 0/Adjuvants, Immunologic; 0/Antibodies; 145155-23-3/interferon beta-1b; 77238-31-4/Interferon-beta ...
  http://www.biomedsearch.com/nih/Cross-sectional-study-assessing-long/20530324.html
*  Weight Management Interventions in Adult and Pediatric Asthma Populations: A Systematic Review | OMICS International
Ample evidence suggests a dose-response relationship between increasing weight and level of asthma risk or reduced asthma ... Evidence also suggests a dose-response relationship between increasing body mass index (BMI) and risk of incident asthma [10-12 ... immunologic, hormonal, and genetic factors may link obesity and asthma [11,14]. To establish causality between obesity and ... Background: Ample evidence suggests a dose-response relationship between increasing weight and level of asthma risk or reduced ...
  https://www.omicsonline.org/open-access/weight-management-interventions-in-adult-and-pediatric-asthma-populations-a-systematic-review-2161-105X.1000232.php?aid=36516
*  A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC) - Full Text View -...
Dose-Response Relationship, Drug. Drug Evaluation. Drug Therapy, Combination. Acquired Immunodeficiency Syndrome. AIDS-Related ... Immunologic Deficiency Syndromes. Acquired Immunodeficiency Syndrome. AIDS-Related Complex. Lentivirus Infections. Retroviridae ... If the initial dose of DS is tolerated without significant side effects, the next group of patients will receive a higher dose ... A third group of patients will be given either a higher or lower dose depending on the results of the earlier groups. Patients ...
  https://clinicaltrials.gov/show/NCT00001009?order=447
*  A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients - Full Text View - ClinicalTrials.gov
Dose-Response Relationship, Drug. Anti-HIV Agents. Additional relevant MeSH terms: HIV Infections. Lentivirus Infections. ... Doses are escalated based on safety assessments: As soon as a dose meets the criteria for 'tolerated' or 'not tolerated', doses ... A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients. This study has been completed. ... To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral ...
  https://clinicaltrials.gov/show/NCT00002218
*  The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients - Full Text View - ClinicalTrials.gov
Dose-Response Relationship, Drug. Adenine. Anti-HIV Agents. Additional relevant MeSH terms: ... Immunologic Deficiency Syndromes. Immune System Diseases. Tenofovir. Antiviral Agents. Anti-Infective Agents. Reverse ... To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy] ... In this double-blind, placebo-controlled study, a total of 60 patients are randomized to receive PMPA prodrug at 1 of 5 doses ...
  https://clinicaltrials.gov/show/NCT00002396?order=71
*  The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients - Full Text View - ClinicalTrials.gov
Dose-Response Relationship, Drug. Cohort Studies. Anti-HIV Agents. Additional relevant MeSH terms: ... Immunologic Deficiency Syndromes. Immune System Diseases. Zidovudine. Antimetabolites. Molecular Mechanisms of Pharmacological ... Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti- ... To identify the adverse event profile that defines the maximum tolerated dose. To characterize the single- and multiple-dose ...
  https://clinicaltrials.gov/show/NCT00002385
*  A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the...
Dose-Response Relationship, Drug. Acquired Immunodeficiency Syndrome. Additional relevant MeSH terms: HIV Infections. Pneumonia ... Immunologic Deficiency Syndromes. Immune System Diseases. Lung Diseases. Respiratory Tract Diseases. Respiratory Tract ... Patients must receive the first dose on this study within 2 weeks of their last dose under study no. 87-71. ... 87-71 entitled, 'A Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three Different Doses of ...
  https://www.clinicaltrials.gov/ct2/show/NCT00002054
*  A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol...
Dose-Response Relationship, Drug. Aerosols. Acquired Immunodeficiency Syndrome. Additional relevant MeSH terms: ... Immunologic Deficiency Syndromes. Immune System Diseases. Lung Diseases. Respiratory Tract Diseases. Respiratory Tract ... A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol ... A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol ...
  https://www.clinicaltrials.gov/ct2/show/NCT00002055
*  The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who...
Dose-Response Relationship, Drug. Aerosols. Acquired Immunodeficiency Syndrome. Additional relevant MeSH terms: ... Immunologic Deficiency Syndromes. Immune System Diseases. Lung Diseases. Respiratory Tract Diseases. Respiratory Tract ... A Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three Different Doses of Aerosol Pentamidine ... To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of 1 of 3 doses of aerosol ...
  https://clinicaltrials.gov/show/NCT00002291?order=116
*  Growth Hormone in the Treatment of HIV-Associated Wasting - Full Text View - ClinicalTrials.gov
Dose-Response Relationship, Drug. Body Composition. Additional relevant MeSH terms: HIV Infections. Cachexia. Wasting Syndrome ... Immunologic Deficiency Syndromes. Immune System Diseases. Emaciation. Weight Loss. Body Weight Changes. Body Weight. Signs and ... The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin ... To establish an optimal dose of Serostim, based on the endpoint of lean body mass (LBM) change.. ...
  https://clinicaltrials.gov/show/NCT00489528?order=51
*  IL-15, IL-12 and BCG enhanced the expression of NKG2D a | Open-i
Dose-Response Relationship, Drug. *Enzyme-Linked Immunosorbent Assay. *Female. *Flow Cytometry. *Humans ... Immunologic Memory/immunology. *Interferon-gamma/immunology/metabolism. *Interleukin-12/immunology/pharmacology. *Leukocytes, ... In addition, IL-22 but not IL-17 was produced by NK cells from PFCs in response to BCG and M.tb-related Ags. More importantly, ... In addition, IL-22 but not IL-17 was produced by NK cells from PFCs in response to BCG and M.tb-related Ags. More importantly, ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4816314_pone.0151721.g006&req=4
*  A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to...
Dose-Response Relationship, Drug. Drug Evaluation. Acquired Immunodeficiency Syndrome. AIDS-Related Complex. ... Immunologic Deficiency Syndromes. Immune System Diseases. Slow Virus Diseases. Didanosine. Antimetabolites. Molecular ... After the maximum tolerated dose (MTD) is determined, an appropriate dosage regimen will then be established for Phase II and ... To expedite this safety study and still be able to maintain close monitoring of the patient's health, an overlapping dosing ...
  https://clinicaltrials.gov/show/NCT00000710?order=469
*  Chemotactic properties of rat immunoglobulins and immune complexes. | DIAL.pr - BOREAL
Dose-Response Relationship, Immunologic ; Immunoglobulin A - physiology ; Immunoglobulin G - physiology ; Immunoglobulins - ... IgG1 and IgG2b also induced a dose-dependent locomotor response of PMN, but the nature of the induced migration was ... Both monomeric and polymeric IgA showed chemotactic activity in a dose-dependent manner. ...
  https://dial.uclouvain.be/pr/boreal/object/boreal:24821
*  A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis - Full Text View - ClinicalTrials.gov
Dose-Response Relationship, Drug. Antifungal Agents. Candidiasis. Esophageal Diseases. MK 0991. Additional relevant MeSH terms ... Immunologic Deficiency Syndromes. Immune System Diseases. Esophageal Diseases. Gastrointestinal Diseases. Digestive System ... In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post- ... An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in ...
  https://clinicaltrials.gov/show/NCT00005921?order=214
*  Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children - Full Text View - ClinicalTrials.gov
Dose-Response Relationship, Drug. Drug Therapy, Combination. Virus Inhibitors. Anti-HIV Agents. Pharmacokinetics. ... Immunologic Deficiency Syndromes. Immune System Diseases. Peginterferon alfa-2b. Antiviral Agents. Anti-Infective Agents. ... The dose level will be increased similarly for up to 4 doses. An optimal dose level is chosen. ... If the dose is tolerated, patients are added and if safety criteria are met, patients are enrolled in the next higher dose ...
  https://clinicaltrials.gov/ct2/show/NCT00006325
*  A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease - Full...
Dose-Response Relationship, Drug. Foscarnet. Acquired Immunodeficiency Syndrome. AIDS-Related Complex. Antiviral Agents. CD4- ... Immunologic Deficiency Syndromes. Immune System Diseases. Foscarnet. Phosphonoacetic Acid. Antiviral Agents. Anti-Infective ... A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease. The ... A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease. ...
  https://clinicaltrials.gov/show/NCT00000729